RU2019127350A - Способы лечения рака с использованием ингибиторов hsp90 - Google Patents
Способы лечения рака с использованием ингибиторов hsp90 Download PDFInfo
- Publication number
- RU2019127350A RU2019127350A RU2019127350A RU2019127350A RU2019127350A RU 2019127350 A RU2019127350 A RU 2019127350A RU 2019127350 A RU2019127350 A RU 2019127350A RU 2019127350 A RU2019127350 A RU 2019127350A RU 2019127350 A RU2019127350 A RU 2019127350A
- Authority
- RU
- Russia
- Prior art keywords
- cancer
- bcl
- inhibitor
- lymphoma
- hsp90 inhibitor
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 24
- 201000011510 cancer Diseases 0.000 title claims 24
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 title claims 18
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 20
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims 19
- 239000003112 inhibitor Substances 0.000 claims 14
- 230000037361 pathway Effects 0.000 claims 11
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 8
- 206010025323 Lymphomas Diseases 0.000 claims 8
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 8
- 230000014509 gene expression Effects 0.000 claims 7
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 6
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 6
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 claims 6
- 229950007866 tanespimycin Drugs 0.000 claims 6
- SWZWQKKFNJGOQM-KBPBESRZSA-N [(2s)-1-[4-[2-[6-amino-8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]purin-9-yl]ethyl]piperidin-1-yl]-1-oxopropan-2-yl] (2s)-2-aminopropanoate Chemical group C1CN(C(=O)[C@H](C)OC(=O)[C@@H](N)C)CCC1CCN1C2=NC=NC(N)=C2N=C1SC(C(=C1)Br)=CC2=C1OCO2 SWZWQKKFNJGOQM-KBPBESRZSA-N 0.000 claims 5
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 claims 5
- 229960001183 venetoclax Drugs 0.000 claims 5
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 4
- QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 claims 4
- 208000032839 leukemia Diseases 0.000 claims 4
- 201000000050 myeloid neoplasm Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- PKYIMGFMRFVOMB-LDLOPFEMSA-N (2R)-2-[5-[3-chloro-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid Chemical compound COc1ccccc1-c1nccc(COc2ccccc2C[C@@H](Oc2ncnc3sc(c(-c4ccc(OCCN5CCN(C)CC5)c(Cl)c4C)c23)-c2ccc(F)cc2)C(O)=O)n1 PKYIMGFMRFVOMB-LDLOPFEMSA-N 0.000 claims 3
- LHGWWAFKVCIILM-UHFFFAOYSA-N 2-(butan-2-ylamino)-4-N-[8-[5-(cyclopropanecarbonyl)pyridin-2-yl]-8-azabicyclo[3.2.1]octan-3-yl]-5-methylbenzene-1,4-dicarboxamide Chemical compound CCC(C)Nc1cc(C(=O)NC2CC3CCC(C2)N3c2ccc(cn2)C(=O)C2CC2)c(C)cc1C(N)=O LHGWWAFKVCIILM-UHFFFAOYSA-N 0.000 claims 3
- NVVPMZUGELHVMH-UHFFFAOYSA-N 3-ethyl-4-[4-[4-(1-methylpyrazol-4-yl)imidazol-1-yl]-3-propan-2-ylpyrazolo[3,4-b]pyridin-1-yl]benzamide Chemical compound CCC1=CC(C(N)=O)=CC=C1N1C2=NC=CC(N3C=C(N=C3)C3=CN(C)N=C3)=C2C(C(C)C)=N1 NVVPMZUGELHVMH-UHFFFAOYSA-N 0.000 claims 3
- HPLNQCPCUACXLM-PGUFJCEWSA-N ABT-737 Chemical group C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HPLNQCPCUACXLM-PGUFJCEWSA-N 0.000 claims 3
- JQNINBDKGLWYMU-GEAQBIRJSA-N CO[C@H]1\C=C\C[C@H](C)[C@@H](C)S(=O)(=O)NC(=O)C2=CC3=C(OC[C@]4(CCCC5=C4C=CC(Cl)=C5)CN3C[C@@H]3CC[C@@H]13)C=C2 Chemical compound CO[C@H]1\C=C\C[C@H](C)[C@@H](C)S(=O)(=O)NC(=O)C2=CC3=C(OC[C@]4(CCCC5=C4C=CC(Cl)=C5)CN3C[C@@H]3CC[C@@H]13)C=C2 JQNINBDKGLWYMU-GEAQBIRJSA-N 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 150000005207 1,3-dihydroxybenzenes Chemical class 0.000 claims 2
- RAYNZUHYMMLQQA-ZEQRLZLVSA-N 2,3,5-trihydroxy-7-methyl-n-[(2r)-2-phenylpropyl]-6-[1,6,7-trihydroxy-3-methyl-5-[[(2r)-2-phenylpropyl]carbamoyl]naphthalen-2-yl]naphthalene-1-carboxamide Chemical compound C1([C@@H](C)CNC(=O)C=2C3=CC(C)=C(C(=C3C=C(O)C=2O)O)C=2C(O)=C3C=C(O)C(O)=C(C3=CC=2C)C(=O)NC[C@H](C)C=2C=CC=CC=2)=CC=CC=C1 RAYNZUHYMMLQQA-ZEQRLZLVSA-N 0.000 claims 2
- QIOCQCYXBYUYLH-YACUFSJGSA-N 3-[1-[(3r)-3-[4-[[4-[4-[3-[2-(4-chlorophenyl)-5-methyl-4-methylsulfonyl-1-propan-2-ylpyrrol-3-yl]-5-fluorophenyl]piperazin-1-yl]phenyl]sulfamoyl]-2-(trifluoromethylsulfonyl)anilino]-4-phenylsulfanylbutyl]piperidine-4-carbonyl]oxypropylphosphonic acid Chemical compound CC(C)N1C(C)=C(S(C)(=O)=O)C(C=2C=C(C=C(F)C=2)N2CCN(CC2)C=2C=CC(NS(=O)(=O)C=3C=C(C(N[C@H](CCN4CCC(CC4)C(=O)OCCCP(O)(O)=O)CSC=4C=CC=CC=4)=CC=3)S(=O)(=O)C(F)(F)F)=CC=2)=C1C1=CC=C(Cl)C=C1 QIOCQCYXBYUYLH-YACUFSJGSA-N 0.000 claims 2
- JKMWZKPAXZBYEH-JWHWKPFMSA-N 5-[3-[4-(aminomethyl)phenoxy]propyl]-2-[(8e)-8-(1,3-benzothiazol-2-ylhydrazinylidene)-6,7-dihydro-5h-naphthalen-2-yl]-1,3-thiazole-4-carboxylic acid Chemical compound C1=CC(CN)=CC=C1OCCCC1=C(C(O)=O)N=C(C=2C=C3C(=N/NC=4SC5=CC=CC=C5N=4)/CCCC3=CC=2)S1 JKMWZKPAXZBYEH-JWHWKPFMSA-N 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 206010000871 Acute monocytic leukaemia Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- QULDDKSCVCJTPV-UHFFFAOYSA-N BIIB021 Chemical compound COC1=C(C)C=NC(CN2C3=NC(N)=NC(Cl)=C3N=C2)=C1C QULDDKSCVCJTPV-UHFFFAOYSA-N 0.000 claims 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical compound O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- QHOPXUFELLHKAS-UHFFFAOYSA-N Thespesin Natural products CC(C)c1c(O)c(O)c2C(O)Oc3c(c(C)cc1c23)-c1c2OC(O)c3c(O)c(O)c(C(C)C)c(cc1C)c23 QHOPXUFELLHKAS-UHFFFAOYSA-N 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- NVGFSTMGRRADRG-IOJSEOPQSA-N chembl553939 Chemical compound CS(O)(=O)=O.O=C1CC(C)(C)CC2=C1C(C(F)(F)F)=NN2C(C=1)=CC=C(C(N)=O)C=1N[C@H]1CC[C@H](OC(=O)CN)CC1 NVGFSTMGRRADRG-IOJSEOPQSA-N 0.000 claims 2
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical class N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 claims 2
- 229930000755 gossypol Natural products 0.000 claims 2
- 229950005277 gossypol Drugs 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 210000004324 lymphatic system Anatomy 0.000 claims 2
- 201000011649 lymphoblastic lymphoma Diseases 0.000 claims 2
- VYXJULKGMXJVGI-XIFFEERXSA-N n-(4-hydroxyphenyl)-3-[6-[(3s)-3-(morpholin-4-ylmethyl)-3,4-dihydro-1h-isoquinoline-2-carbonyl]-1,3-benzodioxol-5-yl]-n-phenyl-5,6,7,8-tetrahydroindolizine-1-carboxamide Chemical compound C1=CC(O)=CC=C1N(C=1C=CC=CC=1)C(=O)C1=C2CCCCN2C(C=2C(=CC=3OCOC=3C=2)C(=O)N2[C@@H](CC3=CC=CC=C3C2)CN2CCOCC2)=C1 VYXJULKGMXJVGI-XIFFEERXSA-N 0.000 claims 2
- IFRGXKKQHBVPCQ-UHFFFAOYSA-N onalespib Chemical compound C1=C(O)C(C(C)C)=CC(C(=O)N2CC3=CC(CN4CCN(C)CC4)=CC=C3C2)=C1O IFRGXKKQHBVPCQ-UHFFFAOYSA-N 0.000 claims 2
- 150000005229 pyrazolopyridines Chemical class 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- 150000003813 tropane derivatives Chemical class 0.000 claims 2
- CVBWTNHDKVVFMI-LBPRGKRZSA-N (2s)-1-[4-[2-[6-amino-8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]purin-9-yl]ethyl]piperidin-1-yl]-2-hydroxypropan-1-one Chemical compound C1CN(C(=O)[C@@H](O)C)CCC1CCN1C2=NC=NC(N)=C2N=C1SC(C(=C1)Br)=CC2=C1OCO2 CVBWTNHDKVVFMI-LBPRGKRZSA-N 0.000 claims 1
- MWTUOSWPJOUADP-XDJHFCHBSA-N (5z)-5-(4-hydroxy-6-oxo-3-propan-2-ylcyclohexa-2,4-dien-1-ylidene)-4-(1-methylindol-5-yl)-1,2,4-triazolidin-3-one Chemical compound O=C1C=C(O)C(C(C)C)=C\C1=C\1N(C=2C=C3C=CN(C)C3=CC=2)C(=O)NN/1 MWTUOSWPJOUADP-XDJHFCHBSA-N 0.000 claims 1
- SWDZPNJZKUGIIH-QQTULTPQSA-N (5z)-n-ethyl-5-(4-hydroxy-6-oxo-3-propan-2-ylcyclohexa-2,4-dien-1-ylidene)-4-[4-(morpholin-4-ylmethyl)phenyl]-2h-1,2-oxazole-3-carboxamide Chemical compound O1NC(C(=O)NCC)=C(C=2C=CC(CN3CCOCC3)=CC=2)\C1=C1/C=C(C(C)C)C(O)=CC1=O SWDZPNJZKUGIIH-QQTULTPQSA-N 0.000 claims 1
- WSMQUUGTQYPVPD-OAHLLOKOSA-N (7r)-2-amino-7-[4-fluoro-2-(6-methoxypyridin-2-yl)phenyl]-4-methyl-7,8-dihydro-6h-pyrido[4,3-d]pyrimidin-5-one Chemical group COC1=CC=CC(C=2C(=CC=C(F)C=2)[C@@H]2NC(=O)C3=C(C)N=C(N)N=C3C2)=N1 WSMQUUGTQYPVPD-OAHLLOKOSA-N 0.000 claims 1
- VFUXSYAXEKYYMB-UHFFFAOYSA-N 2-[2-ethyl-3,5-dihydroxy-6-[3-methoxy-4-(2-morpholin-4-ylethoxy)benzoyl]phenyl]-n,n-bis(2-methoxyethyl)acetamide Chemical compound CCC1=C(O)C=C(O)C(C(=O)C=2C=C(OC)C(OCCN3CCOCC3)=CC=2)=C1CC(=O)N(CCOC)CCOC VFUXSYAXEKYYMB-UHFFFAOYSA-N 0.000 claims 1
- RVJIQAYFTOPTKK-UHFFFAOYSA-N 2-[[6-(dimethylamino)-1,3-benzodioxol-5-yl]sulfanyl]-1-[2-(2,2-dimethylpropylamino)ethyl]imidazo[4,5-c]pyridin-4-amine Chemical compound N1=CC=C2N(CCNCC(C)(C)C)C(SC3=CC=4OCOC=4C=C3N(C)C)=NC2=C1N RVJIQAYFTOPTKK-UHFFFAOYSA-N 0.000 claims 1
- BMZGPNGECPQAGB-UHFFFAOYSA-N 4-[2-amino-4-chloro-7-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]pyrrolo[2,3-d]pyrimidin-5-yl]but-3-ynyl dihydrogen phosphate Chemical compound COC1=C(C)C=NC(CN2C3=NC(N)=NC(Cl)=C3C(C#CCCOP(O)(O)=O)=C2)=C1C BMZGPNGECPQAGB-UHFFFAOYSA-N 0.000 claims 1
- RNCNPRCUHHDYPC-UHFFFAOYSA-N 6-[[6-(1-methylpyrazol-4-yl)imidazo[1,2-b]pyridazin-3-yl]methyl]quinoline Chemical compound C1=NN(C)C=C1C1=NN2C(CC=3C=C4C=CC=NC4=CC=3)=CN=C2C=C1 RNCNPRCUHHDYPC-UHFFFAOYSA-N 0.000 claims 1
- 108091012583 BCL2 Proteins 0.000 claims 1
- -1 BCLXL Proteins 0.000 claims 1
- RVAQIUULWULRNW-UHFFFAOYSA-N Ganetespib Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(O)=NN=2)C=2C=C3C=CN(C)C3=CC=2)=C1O RVAQIUULWULRNW-UHFFFAOYSA-N 0.000 claims 1
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 claims 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 claims 1
- AVDSOVJPJZVBTC-UHFFFAOYSA-N [4-[2-carbamoyl-5-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)-5,7-dihydroindazol-1-yl]anilino]cyclohexyl] 2-aminoacetate Chemical compound O=C1CC(C)(C)CC2=C1C(C(F)(F)F)=NN2C(C=1)=CC=C(C(N)=O)C=1NC1CCC(OC(=O)CN)CC1 AVDSOVJPJZVBTC-UHFFFAOYSA-N 0.000 claims 1
- KUFRQPKVAWMTJO-LMZWQJSESA-N alvespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C1C2=O KUFRQPKVAWMTJO-LMZWQJSESA-N 0.000 claims 1
- 229950007861 alvespimycin Drugs 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 239000013068 control sample Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229950004161 ganetespib Drugs 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 229950005069 luminespib Drugs 0.000 claims 1
- 230000001926 lymphatic effect Effects 0.000 claims 1
- 229950004847 navitoclax Drugs 0.000 claims 1
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- OAKGNIRUXAZDQF-TXHRRWQRSA-N retaspimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(O)C1=CC(O)=C2NCC=C OAKGNIRUXAZDQF-TXHRRWQRSA-N 0.000 claims 1
- SUPVGFZUWFMATN-UHFFFAOYSA-N zelavespib Chemical compound N1=CN=C2N(CCCNC(C)C)C(SC=3C(=CC=4OCOC=4C=3)I)=NC2=C1N SUPVGFZUWFMATN-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762454113P | 2017-02-03 | 2017-02-03 | |
| US62/454,113 | 2017-02-03 | ||
| US201762563991P | 2017-09-27 | 2017-09-27 | |
| US62/563,991 | 2017-09-27 | ||
| US201762587886P | 2017-11-17 | 2017-11-17 | |
| US62/587,886 | 2017-11-17 | ||
| PCT/US2018/016361 WO2018144680A1 (en) | 2017-02-03 | 2018-02-01 | Methods for treating cancer using hsp90 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2019127350A true RU2019127350A (ru) | 2021-03-03 |
| RU2019127350A3 RU2019127350A3 (enExample) | 2021-05-31 |
Family
ID=63038389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019127350A RU2019127350A (ru) | 2017-02-03 | 2018-02-01 | Способы лечения рака с использованием ингибиторов hsp90 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10799508B2 (enExample) |
| EP (1) | EP3576794A1 (enExample) |
| JP (1) | JP2020505433A (enExample) |
| KR (1) | KR20190110128A (enExample) |
| CN (1) | CN110536702A (enExample) |
| AU (1) | AU2018215336A1 (enExample) |
| BR (1) | BR112019016024A2 (enExample) |
| CA (1) | CA3052594A1 (enExample) |
| IL (1) | IL268430A (enExample) |
| MX (1) | MX2019009227A (enExample) |
| RU (1) | RU2019127350A (enExample) |
| TW (1) | TW201840337A (enExample) |
| WO (1) | WO2018144680A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201840337A (zh) | 2017-02-03 | 2018-11-16 | 美商藍治療公司 | 使用ｈｓｐ９０抑制劑治療癌症的方法 |
| WO2019067666A1 (en) * | 2017-09-27 | 2019-04-04 | Lam Therapeutics, Inc. | THERAPEUTIC METHODS RELATING TO HSP90 INHIBITORS |
| WO2020094712A1 (en) * | 2018-11-08 | 2020-05-14 | Glaxosmithkline Intellectual Property Development Limited | Combination of prmt5 inhibitors and bcl-2 inhibitors |
| CN113874016A (zh) | 2019-01-29 | 2021-12-31 | 福宏治疗公司 | 化合物及其用途 |
| AU2020304019A1 (en) * | 2019-06-25 | 2022-01-20 | Tva (Abc), Llc | HSP90-binding conjugates and combination therapies thereof |
| WO2021022163A2 (en) | 2019-07-31 | 2021-02-04 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2021092030A1 (en) | 2019-11-05 | 2021-05-14 | Abbvie Inc. | Dosing regimens for use in treating myelofibrosis and mpn-related disorders with navitoclax |
| US12528825B2 (en) | 2020-01-29 | 2026-01-20 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| EP4101468A4 (en) * | 2020-02-05 | 2024-02-28 | Carna Biosciences, Inc. | Anticancer agent composition |
| KR102683903B1 (ko) * | 2020-09-16 | 2024-07-12 | 한국원자력의학원 | 아리피프라졸을 유효성분으로 함유하는 bcl2 저해제의 항암 효과 증진용 조성물 |
| CN116615195A (zh) * | 2020-09-17 | 2023-08-18 | 阿尔伯爱因斯坦医学院 | 使用bax激活剂的组合治疗 |
| MX2023003205A (es) * | 2020-09-17 | 2023-08-04 | Albert Einstein College Medicine | Terapia combinada mediante agente activador bax. |
| WO2023060137A2 (en) * | 2021-10-05 | 2023-04-13 | Board Of Regents, The University Of Texas System | Methods and compositions comprising b7-h3 binding polypeptides |
| CN114588269B (zh) * | 2022-04-06 | 2023-06-27 | 宁波大学附属人民医院 | Bcl-2抑制剂和HDAC抑制剂的组合物及其用途 |
| WO2024006292A2 (en) * | 2022-06-27 | 2024-01-04 | Foghorn Therapeutics Inc. | Methods of treating cancer |
| CN115957328A (zh) * | 2022-07-13 | 2023-04-14 | 杭州百可生物科技有限公司 | 一种用于治疗白血病的药物组合物以及白血病的治疗方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011060253A2 (en) | 2009-11-13 | 2011-05-19 | Myrexis, Inc. | Methods of treating diseases, pharmaceutical compositions, and pharmaceutical dosage forms |
| EP2533781B1 (en) * | 2010-02-12 | 2016-11-16 | Niiki Pharma Inc. | Method for treating hematological cancers of myeloid origin |
| WO2012148550A1 (en) | 2011-02-25 | 2012-11-01 | Myrexis, Inc. | Prodrugs of therapeutic compounds |
| BR112013027448A2 (pt) * | 2011-04-28 | 2020-09-01 | Sloan-Kettering Institute For Cancer Research | terapia de combinação com hsp90 |
| TW201840337A (zh) | 2017-02-03 | 2018-11-16 | 美商藍治療公司 | 使用ｈｓｐ９０抑制劑治療癌症的方法 |
| WO2019067666A1 (en) | 2017-09-27 | 2019-04-04 | Lam Therapeutics, Inc. | THERAPEUTIC METHODS RELATING TO HSP90 INHIBITORS |
-
2018
- 2018-02-01 TW TW107103636A patent/TW201840337A/zh unknown
- 2018-02-01 BR BR112019016024-8A patent/BR112019016024A2/pt not_active Application Discontinuation
- 2018-02-01 WO PCT/US2018/016361 patent/WO2018144680A1/en not_active Ceased
- 2018-02-01 JP JP2019542191A patent/JP2020505433A/ja not_active Withdrawn
- 2018-02-01 CN CN201880023110.6A patent/CN110536702A/zh active Pending
- 2018-02-01 MX MX2019009227A patent/MX2019009227A/es unknown
- 2018-02-01 KR KR1020197025467A patent/KR20190110128A/ko not_active Ceased
- 2018-02-01 AU AU2018215336A patent/AU2018215336A1/en not_active Abandoned
- 2018-02-01 US US15/885,975 patent/US10799508B2/en not_active Expired - Fee Related
- 2018-02-01 RU RU2019127350A patent/RU2019127350A/ru not_active Application Discontinuation
- 2018-02-01 CA CA3052594A patent/CA3052594A1/en not_active Abandoned
- 2018-02-01 EP EP18704808.7A patent/EP3576794A1/en not_active Withdrawn
-
2019
- 2019-08-01 IL IL268430A patent/IL268430A/en unknown
-
2020
- 2020-09-23 US US16/948,537 patent/US20210030759A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019016024A2 (pt) | 2020-03-31 |
| US10799508B2 (en) | 2020-10-13 |
| RU2019127350A3 (enExample) | 2021-05-31 |
| EP3576794A1 (en) | 2019-12-11 |
| AU2018215336A1 (en) | 2019-09-12 |
| US20210030759A1 (en) | 2021-02-04 |
| MX2019009227A (es) | 2020-02-12 |
| TW201840337A (zh) | 2018-11-16 |
| CA3052594A1 (en) | 2018-08-09 |
| US20180221376A1 (en) | 2018-08-09 |
| CN110536702A (zh) | 2019-12-03 |
| WO2018144680A1 (en) | 2018-08-09 |
| KR20190110128A (ko) | 2019-09-27 |
| JP2020505433A (ja) | 2020-02-20 |
| IL268430A (en) | 2019-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kim et al. | The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models | |
| Kolev et al. | PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells | |
| Mason et al. | Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer | |
| Roschewski et al. | Diffuse large B-cell lymphoma—treatment approaches in the molecular era | |
| Renner et al. | A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma | |
| Ahmed et al. | Selective inhibition of parallel DNA damage response pathways optimizes radiosensitization of glioblastoma stem-like cells | |
| Gingis-Velitski et al. | Host response to short-term, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice | |
| Verma et al. | Targeting of PYK2 synergizes with EGFR antagonists in basal-like TNBC and circumvents HER3-associated resistance via the NEDD4–NDRG1 axis | |
| Li et al. | Proinflammatory factors mediate paclitaxel‐induced impairment of learning and memory | |
| Xia et al. | Therapeutic potential of autophagy in glioblastoma treatment with phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin signaling pathway inhibitors | |
| Golfmann et al. | Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer | |
| JP2020505433A5 (enExample) | ||
| Gonzalez-Santamarta et al. | Resistance to the proteasome inhibitors: lessons from multiple myeloma and mantle cell lymphoma | |
| Kuwahara et al. | Targeting of tumor endothelial cells combining 2 Gy/day of X‐ray with Everolimus is the effective modality for overcoming clinically relevant radioresistant tumors | |
| Singh et al. | Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR-ErbB2 signaling with lapatinib | |
| Zhao et al. | Inhibition of cell proliferation and induction of autophagy by KDM2B/FBXL10 knockdown in gastric cancer cells | |
| Alinari et al. | Bruton's tyrosine kinase inhibitors in B‐cell non‐Hodgkin's lymphomas | |
| Chargari et al. | Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts | |
| Carlo-Stella et al. | A first-in-human study of tenalisib (RP6530), a dual PI3K δ/γ inhibitor, in patients with relapsed/refractory hematologic malignancies: results from the European study | |
| Langdon et al. | SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells | |
| CN106029070A (zh) | 艾日布林和mTOR抑制剂作为治疗癌症的联合疗法的用途 | |
| Wu et al. | Microtubule inhibition causes epidermal growth factor receptor inactivation in oesophageal cancer cells | |
| Postiglione et al. | 5‐aminolaevulinic acid/photo‐dynamic therapy and gefitinib in non‐small cell lung cancer cell lines: a potential strategy to improve gefitinib therapeutic efficacy | |
| NZ630314A (en) | Combination therapy for hematological malignancies | |
| Kozaki et al. | Development of a Bruton’s tyrosine kinase (Btk) inhibitor–ONO-WG-307, a potential treatment for B-cell malignancies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20220121 |